Namodenoson showed a tolerable safety profile consistent with previous studies.

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as ...

Can-Fite BioPharma Ltd. CANF on Wednesday said its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma ...

Detailed price information for Can-Fite Biopharma Ltd ADR (CANF-A) from The Globe and Mail including charting and trades.

The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in ...

Add Yahoo as a preferred source to see more of our stories on Google. The deals, both announced today, are part of an 18-month string of acquisitions in which the parent of social media app Triller ...

Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for ...

London, UK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- The FITE team proudly announces the launch of their groundbreaking platform in the Centralized Finance (CeFi) arena, named FITE—an acronym for "First In ...

WrestleMania week will feature much more than WWE events with dozens of wrestling shows taking place in New York City during the first week in April. And now, wrestling fans won't have to be there to ...

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months ...

In its two latest latest acquisitions, TrillerNet has bought Fite, a streaming platform best known for boxing and ring-sports events, and customer engagement platform Amplify.ai. The deals, both ...